Unnamed: 0,title,date,stock,sentiment
556902.0,"Benzinga's Top Upgrades, Downgrades For May 22, 2020",2020-05-22 10:00:00-04:00,GLMD,positive
556903.0,"B. Riley FBR Downgrades Galmed Pharmaceuticals to Neutral, Lowers Price Target of $8",2020-05-22 06:03:00-04:00,GLMD,negative
556904.0,61 Biggest Movers From Yesterday,2020-05-20 04:50:00-04:00,GLMD,neutral
556905.0,"Raymond James Maintains Outperform on Galmed Pharmaceuticals, Lowers Price Target to $20",2020-05-15 08:30:00-04:00,GLMD,negative
556906.0,"The Daily Biotech Pulse: ASCO Abstracts Create Stock Ripples, Applied DNA's Coronavirus Test Receives EUA, Biopharmx Shareholders Vet Reverse Merger",2020-05-14 08:32:00-04:00,GLMD,positive
556907.0,Galmed Pharmaceuticals Q1 EPS $(0.290) Beats $(0.370) Estimate,2020-05-14 07:04:00-04:00,GLMD,neutral
556908.0,"Earnings Scheduled For May 14, 2020",2020-05-14 05:03:00-04:00,GLMD,neutral
556909.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,GLMD,neutral
556910.0,"The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company",2020-03-20 07:44:00-04:00,GLMD,negative
556911.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-19 10:49:00-04:00,GLMD,negative
556912.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,GLMD,neutral
556913.0,"Stifel Maintains Buy on Galmed Pharmaceuticals, Lowers Price Target to $25",2020-03-13 09:53:00-04:00,GLMD,negative
556914.0,"B. Riley FBR Maintains Buy on Galmed Pharmaceuticals, Lowers Price Target to $11",2020-03-13 07:37:00-04:00,GLMD,negative
556915.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,GLMD,negative
556916.0,Galmed Pharmaceuticals Q4 EPS $(0.39) Misses $(0.34) Estimate,2020-03-12 07:06:00-04:00,GLMD,negative
556917.0,"Earnings Scheduled For March 12, 2020",2020-03-12 04:51:00-04:00,GLMD,neutral
556918.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,GLMD,positive
556919.0,"The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues",2020-03-08 16:14:00-04:00,GLMD,negative
556920.0,140 Biggest Movers From Yesterday,2020-02-28 05:00:00-05:00,GLMD,neutral
556921.0,13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market,2020-02-05 16:11:00-05:00,GLMD,neutral
556922.0,68 Biggest Movers From Yesterday,2020-02-05 05:56:00-05:00,GLMD,neutral
556923.0,"Benzinga's Top Upgrades, Downgrades For February 4, 2020",2020-02-04 09:48:00-05:00,GLMD,positive
556924.0,"Craig-Hallum Initiates Coverage On Galmed Pharmaceuticals with Buy Rating, Announces $18 Price Target",2020-02-04 08:42:00-05:00,GLMD,neutral
556925.0,"Cantor Fitzgerald Assumes Galmed Pharmaceuticals at Overweight, Lowers Price Target To $14",2020-01-30 07:12:00-05:00,GLMD,negative
556926.0,"The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut",2020-01-29 08:30:00-05:00,GLMD,neutral
556927.0,80 Biggest Movers From Yesterday,2019-12-10 05:27:00-05:00,GLMD,neutral
556928.0,48 Stocks Moving In Monday's Mid-Day Session,2019-12-09 12:26:00-05:00,GLMD,neutral
556929.0,72 Biggest Movers From Yesterday,2019-12-05 05:10:00-05:00,GLMD,neutral
556930.0,38 Stocks Moving In Wednesday's Mid-Day Session,2019-12-04 12:02:00-05:00,GLMD,neutral
556931.0,75 Biggest Movers From Yesterday,2019-12-03 05:48:00-05:00,GLMD,neutral
556932.0,44 Stocks Moving In Monday's Mid-Day Session,2019-12-02 12:11:00-05:00,GLMD,neutral
556933.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,GLMD,positive
556934.0,Galmed Pharmaceuticals Q3 EPS $(0.21) Beats $(0.29) Estimate,2019-11-06 07:18:00-05:00,GLMD,neutral
556935.0,58 Biggest Movers From Friday,2019-11-04 07:12:00-05:00,GLMD,neutral
556936.0,50 Stocks Moving In Friday's Mid-Day Session,2019-11-01 13:09:00-04:00,GLMD,neutral
556937.0,"The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",2019-10-11 08:14:00-04:00,GLMD,positive
556938.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-10 11:08:00-04:00,GLMD,negative
556939.0,"The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO",2019-10-10 07:31:00-04:00,GLMD,neutral
556940.0,"The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo",2019-10-03 07:34:00-04:00,GLMD,negative
556941.0,46 Biggest Movers From Yesterday,2019-10-03 05:05:00-04:00,GLMD,neutral
556942.0,31 Stocks Moving In Wednesday's Mid-Day Session,2019-10-02 12:28:00-04:00,GLMD,neutral
556943.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-02 10:55:00-04:00,GLMD,negative
556944.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,GLMD,positive
556945.0,70 Biggest Movers From Yesterday,2019-08-06 04:46:00-04:00,GLMD,neutral
556946.0,New 52-Week Lows For Monday Morning,2019-08-05 13:16:00-04:00,GLMD,negative
556947.0,Galmed Pharmaceuticals Q2 EPS $(0.2) Beats $(0.22) Estimate,2019-08-05 07:04:00-04:00,GLMD,neutral
556948.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,GLMD,neutral
556949.0,"Benzinga's Top Upgrades, Downgrades For July 22, 2019",2019-07-22 09:55:00-04:00,GLMD,positive
556950.0,"Laidlaw & Co. Initiates Coverage On Galmed Pharmaceuticals with Buy Rating, Announces $25 Price Target",2019-07-22 08:47:00-04:00,GLMD,neutral
556951.0,60 Biggest Movers From Friday,2019-07-01 05:01:00-04:00,GLMD,neutral
556952.0,40 Stocks Moving In Friday's Mid-Day Session,2019-06-28 12:19:00-04:00,GLMD,neutral
556953.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,GLMD,neutral
556954.0,Galmed Pharmaceuticals Q1 EPS $(0.17) Beats $(0.2) Estimate,2019-05-07 07:27:00-04:00,GLMD,neutral
556955.0,Galmed Pharma Says it Has Reached an Agreement with the FDA on Key Aspects of its Phase 3/4 ARMOR Study,2019-04-09 07:32:00-04:00,GLMD,positive
556956.0,56 Stocks Moving In Thursday's Mid-Day Session,2019-03-14 12:24:00-04:00,GLMD,neutral
556957.0,35 Stocks Moving In Thursday's Pre-Market Session,2019-03-14 08:07:00-04:00,GLMD,neutral
556958.0,"The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie",2019-03-13 07:27:00-04:00,GLMD,negative
556959.0,Galmed Pharmaceuticals Q4 EPS $(0.18) Misses $(0.13) Estimate,2019-03-13 07:10:00-04:00,GLMD,negative
556960.0,Galmed Reports 'Positive' Results From Pharmacokinetic Split Dose Study Of Aramchol,2019-03-12 08:10:00-04:00,GLMD,neutral
556961.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs",2019-03-10 14:32:00-04:00,GLMD,neutral
556962.0,52 Biggest Movers From Yesterday,2018-12-13 04:54:00-05:00,GLMD,neutral
556963.0,41 Stocks Moving In Wednesday's Mid-Day Session,2018-12-12 12:33:00-05:00,GLMD,neutral
556964.0,Galmed Pharmaceuticals shares are trading up 10.5% after B. Riley initiated coverage on the stock with a Buy rating and a price target of $28.,2018-12-12 10:13:00-05:00,GLMD,positive
556965.0,"B. Riley FBR Initiates Coverage On Galmed Pharmaceuticals with Buy Rating, Announces $28 Price Target",2018-12-12 09:13:00-05:00,GLMD,neutral
556966.0,Galmed  Announces Phase 2 Data for  Aramchol in NASH Presented During Late-Breaking Abstract Oral Session of The Liver Meeting 2018,2018-11-13 11:36:00-05:00,GLMD,neutral
556967.0,"The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut",2018-11-13 07:54:00-05:00,GLMD,negative
556968.0,5 Stocks Moving In Monday's After-Hours Session,2018-11-12 16:57:00-05:00,GLMD,neutral
556969.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-11 09:10:00-05:00,GLMD,neutral
556970.0,"Galmed Pharmaceuticals Q3 EPS $(0.05) Beats $(0.14) Estimate, Sales $1.5M Beat $140K Estimate",2018-11-05 07:09:00-05:00,GLMD,neutral
556971.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,GLMD,neutral
556972.0,71 Biggest Movers From Friday,2018-10-29 05:33:00-04:00,GLMD,neutral
556973.0,"Galmed Pharmaceuticals Q2 EPS $(0.17) Misses $(0.16) Estimate, Sales $270K Inline",2018-08-02 07:04:00-04:00,GLMD,negative
556974.0,"Benzinga's Top Upgrades, Downgrades For July 20, 2018",2018-07-20 09:15:00-04:00,GLMD,positive
556975.0,"Raymond James Initiates Coverage On Galmed Pharmaceuticals with Outperform Rating, Announces $26 Price Target",2018-07-20 07:48:00-04:00,GLMD,neutral
556976.0,38 Biggest Movers From Friday,2018-07-16 04:47:00-04:00,GLMD,neutral
556977.0,30 Stocks Moving In Friday's Mid-Day Session,2018-07-13 12:38:00-04:00,GLMD,neutral
556978.0,Galmed Notches Second Bullish Rating On Aramchol Opportunity,2018-07-13 10:49:00-04:00,GLMD,positive
556979.0,"Galmed Shares Rise 11% Premarket After Stifel Nicolaus Initiated Coverage With A Buy Rating, Price Target $35 Compared With Current Share Price Of $14.30",2018-07-13 09:13:00-04:00,GLMD,positive
556980.0,"Benzinga's Top Upgrades, Downgrades For July 13, 2018",2018-07-13 09:05:00-04:00,GLMD,positive
556981.0,24 Stocks Moving In Friday's Mid-Day Session,2018-07-13 08:03:00-04:00,GLMD,neutral
556982.0,"Stifel Nicolaus Initiates Coverage On Galmed Pharmaceuticals with Buy Rating, Announces $35 Price Target",2018-07-13 07:09:00-04:00,GLMD,neutral
556983.0,44 Biggest Movers From Yesterday,2018-07-13 04:08:00-04:00,GLMD,neutral
556984.0,30 Stocks Moving In Thursday's Mid-Day Session,2018-07-12 12:19:00-04:00,GLMD,neutral
556985.0,Cantor Fitzgerald Makes An Uber-Bullish Call On Galmed Pharmaceuticals,2018-07-12 12:11:00-04:00,GLMD,neutral
556986.0,25 Stocks Moving In Thursday's Pre-Market Session,2018-07-12 08:00:00-04:00,GLMD,neutral
556987.0,6 Stocks Moving In Wednesday's After-Hours Session,2018-07-11 16:58:00-04:00,GLMD,neutral
556988.0,Galmed Shares Gain 12.8% After Hours Following Cantor Fitzgerald Initiation At Overweight With $59 PT Compared With Closing Price Of $10.55,2018-07-11 16:40:00-04:00,GLMD,positive
556989.0,"Cantor Fitzgerald Initiates Coverage On Galmed Pharmaceuticals with Overweight Rating, Announces $59 Price Target",2018-07-11 16:14:00-04:00,GLMD,negative
556990.0,"Benzinga's Daily Biotech Pulse: Sarepta's DMD Gene Therapy, Anika's Flunked Trial, Eidos To Commence Trading",2018-06-20 08:36:00-04:00,GLMD,negative
556991.0,Galmed Pharmaceuticals Prices 5M Share Public Offering of Ordinary Shares @$15/Share,2018-06-20 04:04:00-04:00,GLMD,positive
556992.0,21 Stocks Moving In Tuesday's Pre-Market Session,2018-06-19 08:14:00-04:00,GLMD,neutral
556993.0,A Peek Into The Markets: US Stock Futures Point To A Lower Open,2018-06-18 07:11:00-04:00,GLMD,negative
556994.0,Galmed Pharmaceuticals Announces Proposed Offering of $75M,2018-06-18 06:31:00-04:00,GLMD,neutral
556995.0,"Benzinga's Biggest Movers For The Week Of June 11, 2018",2018-06-15 16:10:00-04:00,GLMD,neutral
556996.0,40 Biggest Movers From Yesterday,2018-06-15 04:56:00-04:00,GLMD,neutral
556997.0,31 Stocks Moving In Wednesday's Mid-Day Session,2018-06-13 12:22:00-04:00,GLMD,neutral
556998.0,10 Biggest Price Target Changes For Wednesday,2018-06-13 09:49:00-04:00,GLMD,neutral
556999.0,"Maxim Group Maintains Buy on Galmed Pharmaceuticals, Raises Price Target to $30",2018-06-13 08:02:00-04:00,GLMD,neutral
557000.0,25 Stocks Moving In Wednesday's Pre-Market Session,2018-06-13 08:00:00-04:00,GLMD,neutral
557001.0,"Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111",2018-06-13 07:48:00-04:00,GLMD,negative
557002.0,42 Biggest Movers From Yesterday,2018-06-13 05:31:00-04:00,GLMD,neutral
557003.0,Mid-Afternoon Market Update: Enzo Biochem Falls After Q3 Results; Galmed Pharmaceuticals Shares Surge,2018-06-12 14:32:00-04:00,GLMD,positive
557004.0,Mid-Day Market Update: RH Rises On Earnings Beat; Griffon Shares Plunge,2018-06-12 12:41:00-04:00,GLMD,positive
557005.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Jun. 12, 2018",2018-06-12 12:31:00-04:00,GLMD,positive
557006.0,41 Stocks Moving In Tuesday's Mid-Day Session,2018-06-12 12:29:00-04:00,GLMD,neutral
557007.0,Galmed Shares More Than Double As It Hits Bullseye With Fatty Liver Candidate,2018-06-12 11:47:00-04:00,GLMD,positive
557008.0,Galmed Shares Up 200% After Co.'s 6 mg Aramchol NASH Candidate Earlier Received Regulatory Approvable Endpoint; Aramchol Showed NASH Resolution Without Worsening Of Fibrosis In Patients,2018-06-12 10:59:00-04:00,GLMD,positive
557009.0,Mid-Morning Market Update: Markets Mostly Higher; Lands' End Posts Upbeat Q1 Results,2018-06-12 10:16:00-04:00,GLMD,neutral
557010.0,"Benzinga's Daily Biotech Pulse: Galmed Rips Higher On Positive NASH Data, Enzo Biochem Falls On Earnings, Pfenex Licenses Osteoporosis Candidate",2018-06-12 08:47:00-04:00,GLMD,positive
557011.0,"Galmed's 600 mg Aramchol Achieved Regulatory Approvable Endpoint Showing NASH Resolution Without Worsening Of Fibrosis, In NASH Patients, In the Global Phase 2b ARREST 52-Week Study",2018-06-12 07:13:00-04:00,GLMD,negative
557012.0,"Galmed Pharmaceuticals Q1 EPS $0.17 Does Not Compare To $(0.24) Estimate, Sales $268K Miss $300K Estimate",2018-05-09 07:05:00-04:00,GLMD,negative
557013.0,35 Biggest Movers From Yesterday,2018-04-04 04:20:00-04:00,GLMD,neutral
557014.0,Galmed Pharmaceuticals Prices 1M Share Offering At $6/Share,2018-04-03 07:01:00-04:00,GLMD,positive
557015.0,55 Biggest Movers From Yesterday,2018-03-16 05:14:00-04:00,GLMD,neutral
557016.0,Galmed Pharmaceuticals Shares Up 4.8% After Maxim Group Upgraded The Stock Earlier To Buy,2018-03-15 13:30:00-04:00,GLMD,positive
557017.0,44 Stocks Moving In Thursday's Mid-Day Session,2018-03-15 13:28:00-04:00,GLMD,neutral
557018.0,Aramchol's Failed Past Isn't Its Future; Galmed Gets An Upgrade,2018-03-15 13:12:00-04:00,GLMD,negative
557019.0,"Benzinga's Top Upgrades, Downgrades For March 15, 2018",2018-03-15 09:36:00-04:00,GLMD,positive
557020.0,23 Stocks Moving In Thursday's Pre-Market Session,2018-03-15 08:13:00-04:00,GLMD,neutral
557021.0,Maxim Group Upgrades Galmed Pharmaceuticals to Buy,2018-03-15 07:25:00-04:00,GLMD,neutral
557022.0,"Galmed Shares Down 5.5% Following Larger-Than-Expected Q4 Loss, Revenue Miss",2018-03-13 12:29:00-04:00,GLMD,negative
557023.0,"Galmed Pharmaceuticals Reports Q4 EPS $(0.27) vs $(0.22) Est., Sales $274K vs $290K Est.",2018-03-13 07:08:00-04:00,GLMD,neutral
557024.0,45 Biggest Movers From Friday,2018-02-20 04:50:00-05:00,GLMD,neutral
557025.0,36 Stocks Moving In Friday's Mid-Day Session,2018-02-16 12:25:00-05:00,GLMD,neutral
557026.0,46 Biggest Movers From Yesterday,2018-02-16 05:19:00-05:00,GLMD,neutral
557027.0,"Galmed Shares Rebounding Thurs. Following Major Selloff Wed. As ARRIVE Trial Did Not Meet Primary Endpoint; Stock Fell 46% On Wed., Is Up ~28% Thurs.",2018-02-15 13:57:00-05:00,GLMD,positive
557028.0,40 Stocks Moving In Thursday's Mid-Day Session,2018-02-15 12:11:00-05:00,GLMD,neutral
557029.0,"SunTrust Reduces Galmed Pharmaceuticals Price Target From $19 To $15 Based On Results And Implications On Read-Out Of PHase IIB ARREST Study; Lowered Probability Of Success For aramchol In Their DCF, NPV Models From 25% To 20%",2018-02-15 11:49:00-05:00,GLMD,neutral
557030.0,42 Biggest Movers From Yesterday,2018-02-15 04:43:00-05:00,GLMD,neutral
557031.0,Mid-Afternoon Market Update: Dow Jumps Over 200 Points; Fossil Group Shares Climb On Upbeat Earnings,2018-02-14 14:52:00-05:00,GLMD,positive
557032.0,36 Stocks Moving In Wednesday's Mid-Day Session,2018-02-14 12:52:00-05:00,GLMD,neutral
557033.0,Mid-Day Market Update: U.S. Stocks Turn Higher; Tetraphase Pharmaceuticals Shares Plummet,2018-02-14 12:37:00-05:00,GLMD,positive
557034.0,Galmed Pharma Shares Down 52.8% After Top Line Data From ARRIVE Study Did Not Meet Primary Endpoint,2018-02-14 12:08:00-05:00,GLMD,positive
557035.0,Mid-Morning Market Update: Markets Mostly Lower; Groupon Profit Misses Views,2018-02-14 10:07:00-05:00,GLMD,negative
557036.0,Maxim Group Downgrades Galmed Pharmaceuticals to Hold,2018-02-14 09:18:00-05:00,GLMD,neutral
557037.0,"A Peek Into The Markets: U.S. Stock Futures Rise Ahead Of Earnings, Economic Reports",2018-02-14 07:24:00-05:00,GLMD,neutral
557038.0,Galmed Pharma's Top Line Data From the ARRIVE Study Did Not Meet its Primary Endpoint,2018-02-14 07:12:00-05:00,GLMD,positive
557039.0,Galmed Therapeutics Reports Co. Granted 'Preferred Technological Enterprise' Status,2018-02-07 09:10:00-05:00,GLMD,positive
557040.0,Galmed Pharma Says it Has Been Granted a Lower Corporate Tax Rate by Israeli Officials,2018-02-07 07:17:00-05:00,GLMD,negative
557041.0,"SunTrust Remains Bullish On Galmed Ahead Of Phase II Data On ARRIVE, Says The Company Guided For A Mid-February Release And Data Could Be An Inflection Point For The Company",2018-02-05 09:23:00-05:00,GLMD,neutral
557042.0,48 Biggest Movers From Yesterday,2018-01-09 06:07:00-05:00,GLMD,neutral
557043.0,38 Stocks Moving In Monday's Mid-Day Session,2018-01-08 12:20:00-05:00,GLMD,neutral
557044.0,"Shares Of Galmed Pharmaceuticals Up 10.12%; Earlier 6-K Highlighted Clinical Program, Expectation For Study Data During Q1 and Q2 2018",2018-01-03 15:05:00-05:00,GLMD,positive
557045.0,7 Stocks Moving In Tuesday's After-Hours Session,2017-12-26 17:08:00-05:00,GLMD,neutral
557046.0,Galmed Pharma 6-K Shows Registration For $35M ATM Offering,2017-12-22 16:17:00-05:00,GLMD,neutral
557047.0,"Galmed Pharma 13G Filing From 683 Capital Mgmt. Shows Slightly Increased Stake From ~549K Shares As Of End Of Last Qtr. To ~649K Shares, Or ~5.1% Stake",2017-12-18 17:19:00-05:00,GLMD,positive
557048.0,"Roth Capital Initiates Coverage On Galmed Pharmaceuticals Ltd with Buy Rating, Announces $32.00 Price Target",2017-11-15 08:46:00-05:00,GLMD,neutral
557049.0,"Galmed Pharmaceuticals Reports Q3 EPS $(0.23) vs $(0.26) Est., Sales $273K vs $320K Est.",2017-11-09 07:27:00-05:00,GLMD,neutral
557050.0,"Seaport Global Initiates Coverage On Galmed Pharmaceuticals Ltd. - Ordinary Shares with Buy Rating, Announces $19.00 Price Target",2017-10-06 09:56:00-04:00,GLMD,positive
557051.0,Galmed Says Top Line Arrest Study Data Expected To Be Available In Q2 2018,2017-10-05 08:07:00-04:00,GLMD,negative
557052.0,Galmed Prices Direct Offering Of Common Stock At $7.10/Share,2017-08-03 17:42:00-04:00,GLMD,neutral
557053.0,"Galmed Pharma Q2 EPS $(0.22) vs $(0.27) Est., Sales $300K vs $360K Ests.",2017-07-31 06:10:00-04:00,GLMD,neutral
557054.0,"Galmed Pharma Reports Q1 EPS $(0.26) vs $(0.38) Est., Sales $268K vs $260K Est.",2017-05-15 08:10:00-04:00,GLMD,neutral
557055.0,"Galmed Pharmaceuticals Reports That Data Suggest A Dual Effect Of Aramchol on Fibrosis, Improvement Of Fatty Acid Oxidation; Also Suggests Direct Impact On Collagen Producing Cells Which Results In Reversing Fibrosis",2017-04-05 08:11:00-04:00,GLMD,positive
557056.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-03-28 08:28:00-04:00,GLMD,neutral
557057.0,"Galmed Pharma Q4 EPS $(0.40) vs $(0.30) Est, Sales $274K vs $530K Est",2017-03-23 07:32:00-04:00,GLMD,neutral
557058.0,"H.C. Wainwright Remains Positive On Galmed Pharma As ARREST Enrollment Accelerates, Sees Possible Completion By Year End, Maintains Buy And $13 PT",2016-11-07 12:33:00-05:00,GLMD,positive
557059.0,"Galmed Pharma Reports Q3 EPS $(0.34) vs $(0.39) Est., Sales $193K",2016-11-07 08:03:00-05:00,GLMD,neutral
557060.0,"Exclusive: SunTrust Top Analysts Explain Fatty Liver Diseases, Galmed's Potential In The Space",2016-10-18 13:32:00-04:00,GLMD,positive
557061.0,Galmed Pharma Reports Raised ~$5M to Date Under ATM Program,2016-09-29 09:03:00-04:00,GLMD,neutral
557062.0,"Galmed Pharma Reports Deal with University of California, San Diego Related to Investigator-Initiated Clinical Trial Agreement to Assess Aramcholâ„¢ Effects Juvenile Population",2016-09-22 11:12:00-04:00,GLMD,positive
557063.0,NASH Sympathy Plays On Tobira Therapeutics Deal,2016-09-20 14:43:00-04:00,GLMD,positive
557064.0,18 Biggest Mid-Day Gainers For Tuesday,2016-09-20 12:43:00-04:00,GLMD,neutral
557065.0,"Conatus Pharma Shares Trading Up 27% on the Heels of Deal for Tobira Therapeutics; Also Watching Galmed Pharma, Galectin Therapeutics, Enanta Pharma, Intercept",2016-09-20 10:58:00-04:00,GLMD,positive
557066.0,Galmed Pharmaceuticals Names Dr. Liat Hayardeny Chief Scientific Officer,2016-09-08 08:33:00-04:00,GLMD,neutral
557067.0,Galmed Pharmaceuticals Reports Q2 EPS $(0.39) vs. Est. $(0.35),2016-08-03 08:06:00-04:00,GLMD,neutral
557068.0,Galmed Pharmaceuticals Names Dr. Ran Oren CEO,2016-08-01 08:01:00-04:00,GLMD,neutral
557069.0,Galmed Pharmaceuticals and SAMIL Pharm Sign a License Agreement for the Commercialization of Aramchol in Korea,2016-07-28 08:01:00-04:00,GLMD,positive
557070.0,"Galmed Pharmaceuticals, Weizmann Institute of Science to enter a research Partnership agreement to assess Aramchol effects on microbiome",2016-06-30 08:02:00-04:00,GLMD,positive
557071.0,Galmed Pharmaceuticals Says Ongoing Phase IIB ARREST Trial Expanded To China,2016-06-07 11:04:00-04:00,GLMD,negative
557072.0,Galmed Pharma Reports Expansion of Ongoing Phase IIb ARREST Study to China,2016-06-07 08:07:00-04:00,GLMD,negative
557073.0,Galmed Pharmaceuticals Reports Q1 EPS $(0.36) vs. Est. $(0.33),2016-05-16 08:03:00-04:00,GLMD,neutral
557074.0,"Mount Sinai, Galmed Pharmaceuticals Partner On Phase IIa Trial To Evaluate AramcholTM With Vitamin D For Treatment Of Patients With Fibrotic Nonalcoholic Fatty Liver Disease",2016-05-03 08:06:00-04:00,GLMD,positive
557075.0,Galmed Pharmaceuticals Aramchol Shows Significant Anti-Fibrotic Effect In Pre-Clinical Fatty Liver Disease Model,2016-03-30 08:06:00-04:00,GLMD,positive
557076.0,"H.C. Wainwright Assumes Galmed Pharmaceuticals at Buy, Announces $22.00 PT",2016-03-28 07:08:00-04:00,GLMD,neutral
557077.0,Mid-Morning Market Update: Markets Open Lower; G-III Apparel Misses Q4 Expectations,2016-03-22 09:49:00-04:00,GLMD,negative
557078.0,"Galmed Phama Reports FY15 EPS $(0.96), Inline",2016-03-22 07:31:00-04:00,GLMD,neutral
557079.0,"Earnings Scheduled For March 22, 2016",2016-03-22 04:04:00-04:00,GLMD,neutral
557080.0,Galmed Pharmaceuticals Reports the Enrollment of the Initial Patient in the ARRIVE Study,2016-03-01 08:34:00-05:00,GLMD,neutral
557081.0,Galmed Pharma. Chief Medical Officer Dr. Maya Halpern To Retire,2016-02-11 08:05:00-05:00,GLMD,neutral
557082.0,"Galmed Reports FDA Clearance of IND of Aramachol for Treatment of HIV-Associated Lipodystrophy, Nonalcoholic Fatty Liver Disease",2015-12-01 08:05:00-05:00,GLMD,neutral
557083.0,Galmed Pharma Reports Q3 EPS $(0.23) vs $(0.29) Est.,2015-11-09 08:09:00-05:00,GLMD,neutral
557084.0,Galmed Pharma Reports Q2 Loss of $0.21/Share vs Loss of $0.25/Share,2015-08-13 07:45:00-04:00,GLMD,negative
557085.0,"Roth Still Loves Galmed Pharma, Keeps $20 Price Target And 'Buy' Rating",2015-07-08 21:26:00-04:00,GLMD,positive
557086.0,"Roth's Piros Reiterates Buy, Price Target Of $20 On Galmed Pharmaceuticals After Aramchol Development",2015-07-08 15:35:00-04:00,GLMD,neutral
557087.0,Galmed Pharma Reports Launch of Development of Aramchol Non-Invasive Companion Diagnostic Program,2015-07-08 08:12:00-04:00,GLMD,neutral
557088.0,"Galmed Pharmaceuticals Enters Research, Option & License Agreement As Well As Share Purchase Agreement With One Way Liver Genomics For Development Of Non-Invasive Blood Test Diagnostic Tool",2015-07-08 08:09:00-04:00,GLMD,positive
557089.0,"H.C. Wainwright Initiates Coverage on Galmed Pharmaceuticals at Buy, Announces $21.00 PT",2015-06-23 07:07:00-04:00,GLMD,neutral
557090.0,Galmed Pharma Reports Q1 Loss of $0.22/Share vs Loss of $0.36/Share Est.,2015-05-13 07:04:00-04:00,GLMD,negative
557091.0,Benzinga's Top Initiations,2015-04-15 08:45:00-04:00,GLMD,positive
557092.0,Roth Capital Initiates Galmed Pharmaceuticals At Buy,2015-04-15 08:05:00-04:00,GLMD,neutral
557093.0,"Roth Capital Initiates Coverage on Galmed Pharmaceuticals at Buy, Announces $20.00 PT",2015-04-15 06:31:00-04:00,GLMD,neutral
557094.0,F-3 from Galmed Pharma Shows Registration for $150M Common Stock Shelf Offering,2015-03-31 16:09:00-04:00,GLMD,neutral
557095.0,Galmed Pharmaceuticals FY14 EPS $(0.88),2015-03-31 08:09:00-04:00,GLMD,neutral
557096.0,"Galmed Pharmaceuticals Announces the Beginning of Enrollment in its Phase IIb ARREST Trial for the Treatment of NASH, as well as the Expansion of the Study to the United States",2015-03-09 08:06:00-04:00,GLMD,positive
557097.0,13G: Allen Baharaff Reports 34.9% Stake In Galmed Pharmaceuticals,2015-01-13 15:32:00-05:00,GLMD,neutral
557098.0,13G:  Chaim Hurvitz Reports 9% Stake In Galmed Pharma.,2015-01-13 15:30:00-05:00,GLMD,neutral
557099.0,Galmed Pharmaceuticals Announces the Appointment of Josh Blacher as CFO,2015-01-05 08:04:00-05:00,GLMD,neutral
557100.0,Morning Market Losers,2014-12-26 10:10:00-05:00,GLMD,negative
557101.0,Galmed Pharmaceuticals Completes Analysis Of A Pharmacokinetic Study Of Aramchol In Healthy Volunteers,2014-12-01 08:20:00-05:00,GLMD,positive
557102.0,Galmed Pharmaceuticals Announces First Administration Of Aramchol In Its Phase IIa Trial For the Treatment Of Cholesterol Gallstones,2014-11-13 08:12:00-05:00,GLMD,neutral
557103.0,"Galmed Pharmaceuticals,  Chanan Ray Morris Mutually Agreed to Terminate Consulting Agreement Dated March 4, 2014, Morris to Continue as CFO Through that Date -6-K",2014-10-07 13:07:00-04:00,GLMD,positive
557104.0,UPDATE: MLV & Co Reiterates On Galmed Pharmaceuticals Ltd As Aramchol Grabs FDA Fast Track Designation,2014-09-24 08:13:00-04:00,GLMD,neutral
557105.0,"Midday Gainers From September 23 - Galmed Pharmaceuticals Ltd, Sino-Global Shipping America, Ltd. And More",2014-09-23 12:14:00-04:00,GLMD,neutral
557106.0,"Shares of Galmed Resume Following Third Circuit Breaker, Stock Now Up ~21-23%",2014-09-23 11:06:00-04:00,GLMD,positive
557107.0,"Galmed Pharma Shares Now Halted on Downside Circuit Breaker, Up 43%",2014-09-23 11:00:00-04:00,GLMD,positive
557108.0,"Galmed Pharma Shares Resume, Stock Now Up ~59%",2014-09-23 10:59:00-04:00,GLMD,positive
557109.0,"Galmed Pharma Shares Resume Trade, Rocket 53% Higher, Halted on Second Circuit Breaker",2014-09-23 10:54:00-04:00,GLMD,positive
557110.0,UPDATE: Galmed Pharma Reports FDA Approval of Fast Track Designation for Aramchol,2014-09-23 10:50:00-04:00,GLMD,positive
557111.0,UPDATE: Shares of Galmed Pharma Halted Up 8.6%,2014-09-23 10:49:00-04:00,GLMD,positive
557112.0,"Galmed Pharma Reports FDA Approval of Fast Track Designation for Aramchol for Treatment of NASH, Shares Immediately Halted on Circuit Breaker",2014-09-23 10:48:00-04:00,GLMD,positive
557113.0,Morning Market Movers ,2014-07-28 09:38:00-04:00,GLMD,neutral
557114.0,Galmed Pharma Announces FDA Clearance of IND ,2014-07-22 09:20:00-04:00,GLMD,neutral
557115.0,"MLV Maintains Buy on Galmed Pharma, Maintains $19.00 PT",2014-05-09 06:40:00-04:00,GLMD,neutral
557116.0,Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies,2014-04-28 18:03:00-04:00,GLMD,neutral
557117.0, BioBreakthrough's Tweet: $GLMD virgin NASH play likely to attract some serious attention as $ICPT tests all-time highs,2014-03-14 10:24:00-04:00,GLMD,positive
557118.0,Galmed Pharma IPO Opens at $17 After Pricing at $13.50/Share,2014-03-13 11:01:00-04:00,GLMD,neutral
557119.0,"NASDAQ Says Galmed Pharma IPO Remains in 'Pre-Launch' Status, Trading Should Open 'Shortly'",2014-03-13 10:59:00-04:00,GLMD,neutral
